{"id":209040,"date":"2026-11-19T17:27:40","date_gmt":"2026-11-19T17:27:40","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/209040\/"},"modified":"2026-11-19T17:27:40","modified_gmt":"2026-11-19T17:27:40","slug":"can-new-products-and-acquisitions-revive-pfizers-growth-story","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/209040\/","title":{"rendered":"Can New Products and Acquisitions Revive Pfizer&#8217;s Growth Story?"},"content":{"rendered":"<p style=\"text-align: justify;\">Pfizer&#8217;s <a target=\"_blank\" href=\"https:\/\/www.zacks.com\/stock\/quote\/PFE\" rel=\"noopener nofollow\">PFE<\/a> business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches and strategic acquisitions like Seagen, Metsera and Biohaven.<\/p>\n<p style=\"text-align: justify;\">Its investments in acquisitions and internal research are beginning to deliver results, helping offset declining revenues from older products.<\/p>\n<p style=\"text-align: justify;\">Pfizer\u2019s newly launched and acquired products delivered $3.8 billion in revenues in the third quarter and grew 32% operationally, reflecting strong contributions from products such as Padcev, Nurtec and Lorbrena. While Padcev and Nurtec were added from the acquisitions of Seagen in 2023 and Biohaven in 2022, respectively, Lorbrena is an internally developed product. Its launched and acquired products rose 22% operationally in the first quarter and 18% in the second quarter. Pfizer is investing in these products to mitigate its upcoming loss of exclusivity\u00a0(LOE) headwinds.<\/p>\n<p>Pfizer&#8217;s In-House Pipeline Delivers New Growth Drivers<\/p>\n<p style=\"text-align: justify;\">Some internally developed product launches over the past few years were Abrysvo, an RSV vaccine approved for older adults and for maternal immunization to protect infants; Hympavzi, a once-weekly treatment for hemophilia A or B with or without inhibitors, Elrexfio, a BCMA-targeted bispecific antibody for relapsed or refractory multiple myeloma and Litfulo, for severe alopecia areata.<\/p>\n<p style=\"text-align: justify;\">During the first nine months of 2026, Abrysvo generated worldwide revenues of $691 million, up 25% year over year, while Elrexfio recorded sales of $252 million, up 9%. Pfizer does not separately disclose revenues for Hympavzi and Litfulo. Additionally, the company launched Zavzpret, a nasal spray CGRP receptor antagonist for the acute treatment of migraine, in 2023, following its acquisition of the product through the Biohaven transaction in 2022.<\/p>\n<p>PFE\u2019s Acquisitions Complement Internal R&amp;D<\/p>\n<p style=\"text-align: justify;\">Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years. These acquisitions are turning out to be transformative opportunities for the company. Padcev, added from Seagen, contributed almost $2 billion to Pfizer\u2019s total revenues in the first nine months of 2026, up 38% on an operational basis.<\/p>\n<p style=\"text-align: justify;\">Biohaven has also been a strategically important addition for Pfizer. Year to date, Nurtec revenues have risen 29% to $11.3 billion, driven by demand growth.<\/p>\n<p style=\"text-align: justify;\">Overall, revenues from Pfizer\u2019s acquired products grew 37% operationally in the third quarter.<\/p>\n<p style=\"text-align: justify;\">The November 2025 acquisition of obesity drugmaker Metsera added novel clinical-stage incretin and amylin programs, which are expected to generate billions of dollars in peak sales. A key candidate added from the Metsera deal is berobenatide.<\/p>\n<p style=\"text-align: justify;\">Berobenatide is being developed for weekly and monthly dosing for obesity and obesity-related conditions, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags behind leaders like Eli Lilly<a target=\"_blank\" href=\"https:\/\/www.zacks.com\/stock\/quote\/LLY\" rel=\"noopener nofollow\">LLY<\/a> and Novo Nordisk<a target=\"_blank\" href=\"https:\/\/www.zacks.com\/stock\/quote\/NVO\" rel=\"noopener nofollow\">NVO<\/a>.<\/p>\n<p style=\"text-align: justify;\">The currently available and highly popular weight loss GLP therapies, Eli Lilly\u2019s Zepbound and Novo Nordisk\u2019s Wegovy, are weekly injections. On the other hand, Pfizer\u2019s berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing.<\/p>\n<p>Will Pfizer&#8217;s New and Acquired Drugs Fuel Future Growth?<\/p>\n<p style=\"text-align: justify;\">Overall, Pfizer&#8217;s new and acquired products are gradually changing its growth story from one heavily influenced by COVID-19 revenues to a more diversified business driven by oncology, specialty medicines, vaccines and migraine treatments.<\/p>\n<p style=\"text-align: justify;\">Pfizer expects its recently launched and acquired products and a strong pipeline to help it return to growth from 2029 onward. Pfizer expects a risk-adjusted high single-digit revenue CAGR toward the end of the decade \u2014 from year-end 2028 through year-end 2033.<\/p>\n<p style=\"text-align: justify;\">Newer products are becoming increasingly important to the company&#8217;s long-term growth, although their gains have not yet translated into strong overall revenue growth.<\/p>\n<p>PFE\u2019s Price Performance, Valuation and Estimates<\/p>\n<p style=\"text-align: justify;\">Pfizer\u2019s stock has risen 12.9% so far this year compared with an increase of 24.2% for the <a target=\"_blank\" href=\"https:\/\/www.zacks.com\/stocks\/industry-rank\/industry\/large-cap-pharmaceuticals-225\" rel=\"noopener nofollow\">industry.<\/a><\/p>\n<p><img decoding=\"async\" alt=\"Zacks Investment Research\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/SYNDSRC\/813a37f62f14ff71d5daff0f0bc6bdb3\/195560.jpg%3Fv%3D473438337\" style=\"height: 310px; width: 600px;\"\/>Image Source: Zacks Investment Research<\/p>\n<p>From a valuation standpoint, Pfizer appears attractive relative to the industry. Going by the price\/earnings ratio, Pfizer\u2019s shares currently trade at 9.45 forward earnings, significantly lower than 19.50 for the industry but slightly above the stock\u2019s five-year mean of 9.25. The stock is also trading below most large drugmakers like Lilly, Novo Nordisk, AstraZeneca, AbbVie, J&amp;J and others.<\/p>\n<p><img decoding=\"async\" alt=\"Zacks Investment Research\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/SYNDSRC\/813a37f62f14ff71d5daff0f0bc6bdb3\/195561.jpg%3Fv%3D1070405104\" style=\"height: 310px; width: 600px;\"\/>Image Source: Zacks Investment Research<\/p>\n<p>The Zacks Consensus Estimate for 2026 earnings per share has risen from $2.95 to $3.01, while that for 2027 has risen from $2.95 to $2.96 over the past 30 days.<\/p>\n<p><img decoding=\"async\" alt=\"Zacks Investment Research\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/SYNDSRC\/813a37f62f14ff71d5daff0f0bc6bdb3\/195559.jpg%3Fv%3D1525658667\" style=\"height: 310px; width: 600px;\"\/>Image Source: Zacks Investment Research<\/p>\n<p>Pfizer has a Zacks Rank #3 (Hold) at present. You can see\u00a0<a target=\"_blank\" href=\"https:\/\/www.zacks.com\/stocks\/buy-list\/?ADID=zp_1link&amp;ICID=zpi%20_1link\" rel=\"noopener nofollow\">the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here<\/a>.<\/p>\n<p>Beyond Nvidia: AI&#8217;s Second Wave Is Here<\/p>\n<p>The AI revolution has already minted millionaires. But the stocks everyone knows about aren&#8217;t likely to keep delivering the biggest profits. AI\u2019s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.<\/p>\n<p><a style=\"font-weight:bold\" href=\"https:\/\/www.zacks.com\/registration\/ultimatetrader\/welcome\/eoffer\/4e87?add=2205&amp;adid=SYND_BARCHARTL_ZU_AIBOOMREPORTA_ANALYSTBLOG_252_IND_11192026_3032530&amp;cid=CS-BARCHARTL-FT-analyst_blog%7Cquick_take-3032530\" rel=\"noopener nofollow\" target=\"_blank\">See Stocks Now &gt;&gt;<\/a><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.zacks.com\/stock\/news\/3032530\/can-new-products-and-acquisitions-revive-pfizer-s-growth-story?cid=CS-BARCHARTL-FT-analyst_blog%7Cquick_take-3032530\" rel=\"noopener nofollow\">This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.zacks.com\/\" rel=\"noopener nofollow\">Zacks Investment Research<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Pfizer&#8217;s PFE business mix has changed significantly over the past few years. During the pandemic, the company became&hellip;\n","protected":false},"author":2,"featured_media":209041,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[5921,5918,5917,5920,5919,5922,272,3858,3859,4011],"class_list":["post-209040","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-futures","tag-index-market-quote","tag-index-market-quotes","tag-index-market-symbol","tag-index-market-symbols","tag-indices","tag-novo-nordisk","tag-novo-nordisk-a-s-adr","tag-nvo","tag-the-globe-and-mail"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117644286158855106","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/209040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=209040"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/209040\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/209041"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=209040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=209040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=209040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}